Source: Gordon Thompson
Understanding ROIC and WACC in the Biopharmaceutical Sector
Within the biopharmaceutical sector, companies like Ardelyx, Inc. (NASDAQ:ARDX), Akebia Therapeutics (AKBA), Kala Pharmaceuticals (KALA), and Aldeyra Therapeutics (ALDX) are constantly striving to develop innovative therapies for unmet medical needs. Despite their shared goals, these firms each display varying degrees of capital efficiency, as evidenced by their Return on Invested Capital (ROIC) and Weighted Average Cost of Capital (WACC) metrics.
ROIC is a profitability ratio that measures how effectively a company uses its capital to generate profits. A positive ROIC indicates that the company is generating more than it costs to fund its operations, while a negative ROIC suggests that the company is not generating enough returns to cover its cost of capital, indicating inefficiencies in capital utilization.
On the other hand, WACC represents the average rate of return a company is expected to provide to all its security holders, including debt holders, equity investors, and preferred equity investors. If a company’s ROIC exceeds its WACC, it is creating value; if the ROIC is less than the WACC, it is destroying value.
A Closer Look at the Companies
Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company that focuses on gastrointestinal and cardiorenal diseases, has a negative ROIC of -24.68%, significantly lower than its WACC of 9.12%. This negative ROIC indicates that Ardelyx is not generating enough returns to cover its cost of capital, suggesting inefficiencies in how it utilizes its capital. This could be a red flag for investors who prioritize efficient capital use and could potentially influence their investment decisions.
Contrarily, Akebia Therapeutics (AKBA), showcases a remarkable ROIC of 346.81% against a WACC of 7.35%. This indicates that Akebia is generating returns far exceeding its cost of capital, making it the most efficient among its peers. This high ROIC to WACC ratio of 47.17 suggests that Akebia is effectively utilizing its capital to generate substantial returns, making it a potentially attractive investment opportunity.
Peer Comparison and Sector Challenges
Peers like Kala Pharmaceuticals (KALA) and Aldeyra Therapeutics (ALDX) also exhibit negative ROICs of -82.67% and -46.04%, respectively. Their ROICs are well below their WACCs, indicating significant inefficiencies in capital utilization. This is similar to Ardelyx, where the cost of capital is not being met by the returns generated. This trend suggests widespread capital utilization challenges in the sector.
CytomX Therapeutics (CTMX) and Cidara Therapeutics (CDTX) also have negative ROICs of -26.27% and -37.65%, respectively. However, CytomX’s ROIC to WACC ratio of -3.09 is slightly better than Ardelyx’s -2.71, indicating a marginally more efficient use of capital.
Despite these challenges, Akebia remains the standout performer in terms of capital efficiency. This demonstrates that even within a sector facing capital utilization challenges, there can be companies that manage to utilize their capital effectively.
Conclusion
The ROIC and WACC metrics offer invaluable insights for investors into the efficiency of a company’s capital use, and can guide investment decisions. While negative ROICs may raise concerns about a company’s capital utilization efficiency, positive ROICs, particularly when they significantly exceed the WACC, highlight potential investment opportunities. However, it’s important to remember that these metrics are just one piece of the puzzle and should be considered alongside other financial and strategic factors.